| 0.497 | 0.042 | 0.497 | Prostaglandin dehydrogenase inhibitor | | |
| 0.436 | 0.004 | 0.436 | MAP kinase 12 inhibitor | | |
| 0.36 | 0.004 | 0.36 | MAP kinase 13 inhibitor | | |
| 0.405 | 0.054 | 0.405 | Thyroid hormone antagonist | | |
| 0.412 | 0.069 | 0.412 | 15-Lipoxygenase inhibitor | | |
| 0.373 | 0.036 | 0.373 | Calcium channel activator | | |
| 0.337 | 0.038 | 0.337 | Pyruvate kinase inhibitor | | |
| 0.302 | 0.005 | 0.302 | MAP kinase 14 inhibitor | | |
| 0.34 | 0.072 | 0.34 | Thyroid hormone beta antagonist | | |
| 0.306 | 0.042 | 0.306 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.29 | 0.03 | 0.29 | DNA methyltransferase I inhibitor | | |
| 0.265 | 0.005 | 0.265 | MAP kinase 11 inhibitor | | |
| 0.252 | 0.027 | 0.252 | Amylase inhibitor | | |
| 0.318 | 0.103 | 0.318 | Calpain 2 inhibitor | | |
| 0.232 | 0.019 | 0.232 | MAP kinase kinase inhibitor | | |
| 0.243 | 0.029 | 0.243 | Heat shock protein 90 alpha antagonist | | |
| 0.227 | 0.016 | 0.227 | Antibacterial (Helicobacter pylori) | | |
| 0.229 | 0.019 | 0.229 | Glutamate receptor antagonist | | |
| 0.25 | 0.048 | 0.25 | DNA methylase inhibitor | | |
| 0.259 | 0.058 | 0.259 | Interleukin antagonist | | |
| 0.285 | 0.085 | 0.285 | Streptokinase A inhibitor | | |
| 0.227 | 0.032 | 0.227 | Cyclooxygenase inhibitor | | |
| 0.198 | 0.014 | 0.198 | DNA directed RNA polymerase inhibitor | | |
| 0.198 | 0.014 | 0.198 | Telomerase inhibitor | | |
| 0.209 | 0.028 | 0.209 | Cyclooxygenase 2 inhibitor | | |
| 0.185 | 0.005 | 0.185 | H+/K+-transporting ATPase inhibitor | | |
| 0.207 | 0.03 | 0.207 | Interleukin 1 antagonist | | |
| 0.181 | 0.011 | 0.181 | HIV-1 reverse transcriptase inhibitor | | |
| 0.325 | 0.155 | 0.325 | MAP kinase 1 inhibitor | | |
| 0.202 | 0.037 | 0.202 | Heat shock protein 90 antagonist | | |
| 0.184 | 0.042 | 0.184 | Cyclooxygenase 1 inhibitor | | |
| 0.225 | 0.09 | 0.225 | Aryl hydrocarbon receptor agonist | | |
| 0.16 | 0.028 | 0.16 | Interleukin 8 antagonist | | |
| 0.243 | 0.119 | 0.243 | Caspase 3 stimulant | | |
| 0.156 | 0.032 | 0.156 | Death-associated protein kinase 1 inhibitor | | |
| 0.18 | 0.057 | 0.18 | ATPase inhibitor | | |
| 0.17 | 0.049 | 0.17 | Cytokine production inhibitor | | |
| 0.129 | 0.008 | 0.129 | Acetyl-CoA transferase inhibitor | | |
| 0.124 | 0.004 | 0.124 | Acetyl-CoA transferase 2 inhibitor | | |
| 0.264 | 0.145 | 0.264 | Histamine release inhibitor | | |
| 0.15 | 0.031 | 0.15 | Check point kinase 2 inhibitor | | |
| 0.204 | 0.09 | 0.204 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | | |
| 0.138 | 0.025 | 0.138 | Interleukin 2 antagonist | | |
| 0.205 | 0.096 | 0.205 | Dyrk kinase inhibitor | | |
| 0.13 | 0.025 | 0.13 | Thioredoxin inhibitor | | |
| 0.147 | 0.043 | 0.147 | Protein kinase (CK2) alpha inhibitor | | |
| 0.129 | 0.028 | 0.129 | MAP kinase kinase 1 inhibitor | | |
| 0.199 | 0.101 | 0.199 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | | |
| 0.275 | 0.178 | 0.275 | DNA polymerase beta inhibitor | | |
| 0.105 | 0.009 | 0.105 | Gonadotropin-releasing hormone receptor agonist | | |
| 0.137 | 0.046 | 0.137 | Sphingosine 1-phosphate receptor 4 antagonist | | |
| 0.131 | 0.042 | 0.131 | Nav1.5 sodium channel blocker | | |
| 0.102 | 0.016 | 0.102 | NMDA receptor glycine site agonist | | |
| 0.112 | 0.028 | 0.112 | p38 MAP kinase inhibitor | | |
| 0.169 | 0.087 | 0.169 | MAP kinase kinase 5 inhibitor | | |
| 0.12 | 0.038 | 0.12 | Phosphodiesterase 7B inhibitor | | |
| 0.141 | 0.061 | 0.141 | Sodium channel (voltage-gated) blocker | | |
| 0.132 | 0.053 | 0.132 | Interleukin 1b antagonist | | |
| 0.107 | 0.028 | 0.107 | NMDA 2 receptor antagonist | | |
| 0.124 | 0.046 | 0.124 | AMP-activated protein kinase stimulant | | |
| 0.185 | 0.108 | 0.185 | ErbB-1 antagonist | | |
| 0.114 | 0.036 | 0.114 | Epidermal growth factor antagonist | | |
| 0.257 | 0.182 | 0.257 | Transcription factor inhibitor | | |
| 0.134 | 0.059 | 0.134 | Epidermal growth factor receptor kinase inhibitor | | |
| 0.18 | 0.106 | 0.18 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.127 | 0.059 | 0.127 | Aurora-B kinase inhibitor | | |
| 0.101 | 0.035 | 0.101 | ErbB-2 antagonist | | |
| 0.076 | 0.011 | 0.076 | Nicotinic acid receptor 1 agonist | | |
| 0.107 | 0.043 | 0.107 | NMDA receptor antagonist | | |
| 0.155 | 0.092 | 0.155 | Dual specificity phosphatase 3 inhibitor | | |
| 0.121 | 0.059 | 0.121 | Microtubule formation inhibitor | | |
| 0.092 | 0.032 | 0.092 | Nav1.8 sodium channel blocker | | |
| 0.082 | 0.024 | 0.082 | Phosphodiesterase VII inhibitor | | |
| 0.249 | 0.192 | 0.249 | DNA directed DNA polymerase inhibitor | | |
| 0.11 | 0.054 | 0.11 | Gastric antisecretory | | |
| 0.228 | 0.175 | 0.228 | GABA C receptor rho-3 antagonist | | |
| 0.243 | 0.191 | 0.243 | Alpha-glucosidase inhibitor | | |
| 0.213 | 0.161 | 0.213 | Thioredoxin glutathione reductase inhibitor | | |
| 0.06 | 0.009 | 0.06 | Acetyl-CoA transferase 1 inhibitor | | |
| 0.106 | 0.059 | 0.106 | Protein kinase (CK2) inhibitor | | |
| 0.063 | 0.017 | 0.063 | Phosphodiesterase 7A inhibitor | | |
| 0.189 | 0.144 | 0.189 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.12 | 0.075 | 0.12 | c-Src kinase inhibitor | | |
| 0.27 | 0.228 | 0.27 | Caspase 9 stimulant | | |
| 0.147 | 0.106 | 0.147 | 3C-like protease (Human coronavirus) inhibitor | | |
| 0.13 | 0.091 | 0.13 | Cytidine deaminase inhibitor | | |
| 0.104 | 0.071 | 0.104 | EphA2 antagonist | | |
| 0.05 | 0.018 | 0.05 | Dihydrofolate reductase inhibitor | | |
| 0.151 | 0.119 | 0.151 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | | |
| 0.192 | 0.161 | 0.192 | Gastrin inhibitor | | |
| 0.093 | 0.062 | 0.093 | Potassium channel (Ca-activated) activator | | |
| 0.069 | 0.041 | 0.069 | MAP kinase kinase 10 inhibitor | | |
| 0.067 | 0.039 | 0.067 | NMDA receptor agonist | | |
| 0.159 | 0.131 | 0.159 | Aldehyde oxidase inhibitor | | |
| 0.055 | 0.027 | 0.055 | Potassium channel (Inward rectifier) activator | | |
| 0.146 | 0.119 | 0.146 | Succinate dehydrogenase inhibitor | | |
| 0.079 | 0.052 | 0.079 | MAP kinase 10 inhibitor | | |
| 0.052 | 0.026 | 0.052 | Potassium channel (ATP-sensitive) activator | | |
| 0.092 | 0.067 | 0.092 | Platelet activating factor alpha antagonist | | |
| 0.069 | 0.045 | 0.069 | Nav1.7 sodium channel blocker | | |
| 0.049 | 0.026 | 0.049 | Fructose-1,6-bisphosphatase inhibitor | | |
| 0.061 | 0.038 | 0.061 | Heat shock protein 90 beta antagonist | | |
| 0.064 | 0.041 | 0.064 | Adrenaline uptake inhibitor | | |
| 0.051 | 0.03 | 0.051 | CC chemokine receptor 2B antagonist | | |
| 0.124 | 0.104 | 0.124 | Src kinase inhibitor | | |
| 0.087 | 0.068 | 0.087 | Glutamate release inhibitor | | |
| 0.074 | 0.055 | 0.074 | Carbonic anhydrase XIII inhibitor | | |
| 0.111 | 0.095 | 0.111 | Sodium channel blocker | | |
| 0.029 | 0.015 | 0.029 | CXC chemokine 2 receptor antagonist | | |
| 0.066 | 0.054 | 0.066 | Prostaglandin-E synthase inhibitor | | |
| 0.051 | 0.041 | 0.051 | NMDA 2B receptor antagonist | | |
| 0.018 | 0.01 | 0.018 | Complement factor 1 inhibitor | | |
| 0.032 | 0.025 | 0.032 | Protein kinase (CK2) beta inhibitor | | |
| 0.078 | 0.071 | 0.078 | Transforming growth factor beta 3 antagonist | | |
| 0.017 | 0.012 | 0.017 | Sodium/hydrogen exchanger inhibitor | | |
| 0.127 | 0.125 | 0.127 | Dual specificity phosphatase inhibitor | | |
| 0.016 | 0.014 | 0.016 | Alpha 2a adrenoreceptor agonist | | |
| 0.067 | 0.066 | 0.067 | Glutamate (mGluR) antagonist | | |